MedTrace Logo

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

NCT00969709 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 724

Last updated 2013-10-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.

Conditions

Interventions

DRUG

Levomilnacipran ER

Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.

DRUG

Levomilnacipran ER

Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.

DRUG

Levomilnacipran ER

Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.

DRUG

Placebo

Matching placebo capsules, oral administration, once daily for 8 weeks.

Sponsors & Collaborators

  • Forest Laboratories

    lead INDUSTRY

Principal Investigators

  • Carl Gommoll, MS · Forest Research Institute, a subsidiary of Forest Laboratories Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00969709 on ClinicalTrials.gov